


PHARMACEUTICAL 2022

Ventyx Biosciences Inc. Rank 160 of 475







Ventyx Biosciences Inc. Rank 160 of 475

The relative strengths and weaknesses of Ventyx Biosciences Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Ventyx Biosciences Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 175% points. The greatest weakness of Ventyx Biosciences Inc. is the variable Net Income, reducing the Economic Capital Ratio by 57% points.

The company's Economic Capital Ratio, given in the ranking table, is -22%, being 255% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	263,020
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	12,283
Liabilities, Non-Current	0
Other Assets	28,208
Other Compr. Net Income	-58
Other Expenses	0
Other Liabilities	0
Other Net Income	-16,599
Property and Equipment	254
Research and Development	58,481
Revenues	0
Selling, General and Administrative Expense	8,666

Output Variable	Value in 1000 USD
Assets	291,482
Liabilities	12,283
Expenses	67,147
Stockholders Equity	279,199
Net Income	-83,746
Comprehensive Net Income	-83,775
Economic Capital Ratio	-22%

